Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 19/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698408 | 0.82 | OPRM1 (0.74) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL5608182 | 0.81 | KCNH2 (1.00) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL5486421 | 0.81 | KCNH2 (0.74) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL5486420 | 0.81 | KCNH2 (0.74) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL4697675 | 0.79 | OPRM1 (0.75) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL4697672 | 0.79 | OPRM1 (0.75) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL5755436 | 0.79 | OPRM1 (0.78) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL4754572 | 0.79 | OPRM1 (0.66) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL4754571 | 0.79 | OPRM1 (0.66) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL7074406 | 0.78 | OPRM1 (0.67) | KCNH2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207876-A1 | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20020025948-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207876-A1 | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRD1, OPRK1, OPRM1 | KCNH2 1279/4885OPRM1 3/4885OPRD1 1/4885 |
| US-20020025948-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRD1, OPRK1, OPRM1 | KCNH2 1279/4885OPRM1 3/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.